NEW YORK, April 14, 2025 /PRNewswire/ — Centri Business Consulting, LLC, one of the industry’s fastest-growing and most respected accounting and advisory firms, announces its schedule for the Centri Capital Conference on Tuesday, April 22, at Nasdaq in New York City.
The Centri Capital Conference will gather attendees from across the capital markets ecosystem and investment community, including investment bankers, private equity investors, and venture capitalists. The conference will offer opportunities to hear from market-shaping businesses, learn from thought-provoking panel discussions, and participate in structured 1on1 meetings.
Panel discussions will include:
The Centri Capital Conference’s fireside chats will allow attendees to hear from the disruptive companies shaping the future of healthcare, life sciences, and more. Fireside chat presenters include:
“The Centri Capital Conference will bring together standout businesses and industry leaders who are shaping today’s dynamic capital markets,” says Michael Aiello, CEO & Managing Partner of Centri. “We are confident this conference will deliver invaluable insights, foster meaningful connections, and empower attendees with the knowledge needed to confidently navigate the evolving capital markets landscape.”
Companies and investors interested in presenting, attending, or sponsoring the Centri Capital Conference can register here.
About Centri Business Consulting, LLC
Centri Business Consulting provides the highest quality advisory consulting services by being reliable and responsive to its clients’ needs. The firm specializes in financial reporting, internal controls, technical accounting research, valuation, mergers & acquisitions, tax, CFO and HR advisory services for companies of various sizes and industries. From complex technical accounting transactions to monthly financial reporting, Centri’s professionals offer the specialized expertise, and multilayered skill sets necessary to ensure projects are completed timely and accurately.
SOURCE Centri Business Consulting
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…